SYMPOSIUM: Perspectives on Oncology Drug Discovery; Immuno-Oncology and the Next Generation

Cambridge UK, March 15, 2018 - The Cambridge Building, Babraham Research Campus

EBabraham Institute, Cambridge UKThis year our annual UK Oncology Drug Discovery symposium focuses on immuno-oncology and future advances in cancer treatment.

Immuno-oncology has revolutionised cancer research, with many novel agents already clinically approved. With continued enhancement of preclinical models and methods, the next generation of immunotherapeutics including combination therapies and new modalities can continue to bring patient benefits.

The symposium will bring together oncology and immuno-oncology R&D and preclinical teams from industry, academia, and medical research to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches.

Discussion Topics Include:

  • How to assess long term antitumour immunotherapeutic efficacy, including combination regimen effects
  • The novel targets for next generation immuno-oncology agents, including CAR-T cell therapy
  • The evolution of preclinical models for improved evaluation of immunotherapeutics

Chairperson

Hazel Jones
Hazel Jones

Oncology Chief of Staff, AstraZeneca

   


Presentations & Speakers

Mark Throsby
Mark Throsby

Executive Vice President, CSO, Merus
Therapeutic bispecific antibodies in oncology: approaches and application - the Merus experience

Liz Hardaker
Elizabeth Hardaker

Head of Oncology In Vivo Pharmacology, AstraZeneca UK
The role of genetically engineered mouse models in profiling immune targeting cancer therapies

   
Dr. Rajendra Kumari
Rajendra Kumari

CSO, CrownBio UK
Preclinical modelling of TME for immunotherapy evaluation

James Legg
James Legg

VP Research and Development, Crescendo Biologics
Developing Humabody VH therapeutics for oncology – small and flexible

       
Tineke Casneuf
Tine Casneuf

Scientific Director, Oncology Translational Research,
Janssen R&D

Immunomodulatory effects of daratumumab in multiple myeloma

Richard Harrop
Richard Harrop

Head of Clinical Analysis,
Oxford BioMedica

Targeting the 5T4 oncofoetal antigen with CAR-T cells

       
Richard Sainson
Richard Sainson

Director in Pharmacology and Translational Research, Kymab
KY1044, a fully human anti-ICOS antibody, elicits long term in vivo anti-tumour efficacy as monotherapy and in combination with immune checkpoint inhibitors

David Liberg
David Liberg

VP Cancer Research, Cantargia
Interleukin-1 receptor accessory protein, a novel target for cancer therapy

Attendance is free, but seats are limited, reserve your space by submitting the registration form today!

Reserve Your Seat Now!

Reserve Your Seat

Your privacy is important to us.
We'll never share your information.

SHARE THIS